Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | PANK1 | Q8TE04 | 1/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | HTR3A | P46098 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966263 | 1.00 | CFD (0.33) | CFDPANK1PANK3PTGER3HPGD | |
| SCHEMBL965278 | 0.92 | CFD (0.33) | CFDPANK1PANK3HPGDALDH1A1 | |
| SCHEMBL965276 | 0.92 | CFD (0.33) | CFDPANK1PANK3HPGDALDH1A1 | |
| SCHEMBL963300 | 0.86 | TP53 (0.35) | PTGER3HPGDALDH1A1POLB | |
| SCHEMBL963301 | 0.86 | TP53 (0.35) | PTGER3HPGDALDH1A1POLB | |
| SCHEMBL962093 | 0.86 | HDAC3 (0.36) | HPGDALDH1A1MAPTPOLBRECQL | |
| SCHEMBL962095 | 0.86 | HDAC3 (0.36) | HPGDALDH1A1MAPTPOLBRECQL | |
| SCHEMBL5112953 | 0.83 | HDAC3 (0.35) | PANK1PANK3HPGDALDH1A1TDP1 | |
| SCHEMBL4565957 | 0.83 | HDAC3 (0.35) | PANK1PANK3HPGDALDH1A1TDP1 | |
| SCHEMBL963601 | 0.81 | ENPP3 (0.42) | PTGER3ALDH1A1PKMKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | CFD 4243/4885PANK1 1818/4885PANK3 2708/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | CFD 4814/4885PANK1 1092/4885PANK3 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.